Resultados de procura - Arlene Chan

Limitar resultados
  1. 1
    Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness

    Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness por Arlene Chan

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

    A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients por Xavier Pivot, P. Koralewski, Jorge Hidalgo, Arlene Chan, Anthony Gonçalvès, Gilberto Schwartsmann, Sylvie Assadourian, Jean‐Pierre Lotz

    Publicado 2008
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer

    Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer por M. D. Green, Prudence A. Francis, Val Gebski, V. Harvey, Christos S. Karapetis, Arlene Chan, Ray Snyder, Akiko Fong, R. Basser, John Forbes

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

    Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer por Rebecca Dent, Geoffrey J. Lindeman, Mark Clemons, Hans Wildiers, Arlene Chan, Nicole McCarthy, Christian F. Singer, Elizabeth Lowe, Claire Watkins, James Carmichael

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

    Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer por D.W. Miles, Sanne Lysbet de Haas, Luc Dirix, Gilles Romieu, Arlene Chan, Xavier Pivot, Piotr Tomczak, Louise Provencher, Javier Cortés, Paul Delmar, S.J. Scherer

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

    First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study por Jonas Bergh, Igor Bondarenko, Mikhail Lichinitser, Annelie Liljegren, Richard Greil, Nataliya L. Voytko, А. Н. Махсон, Javier Cortés, Alain Lortholary, Joachim Bischoff, Arlene Chan, Suzette Delaloge, Xin Huang, Kenneth A. Kern, C. Giorgetti

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial

    45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial por Arlene Chan, B. Moy, Janine Mansi, M.I. Gnant, Carlos H. Barrios, Robert Šeparović, AL Guerrero-Zotano, II Gore, John W. Smith, Richard Bryce, Feng Xu, Alvin Wong, Miguel Martín, Frankie A. Holmes

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Code of practice needed for samples donated by trial participants

    Code of practice needed for samples donated by trial participants por Robert E. Coleman, Arlene Chan, Carlos H. Barrios, David Cameron, Luís Costa, Mitch Dowsett, David J. Harrison, Anthony Howell, Denis Lacombe, Mairead MacKenzie, Miguel Martı́n, Stuart McIntosh, Adrienne Morgan, Martine Piccart, Tanja Španić

    Publicado 2022
    Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  9. 9
    AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

    AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breas... por Luca Gianni, Gilles Romieu, М. Р. Личиницер, Sérgio Serrano, Mauro Mansutti, Xavier Pivot, Paola Mariani, Fabrice André, Arlene Chan, O. N. Lipatov, Stephen Chan, Andrew Wardley, Richard Greil, N. Moore, Sylvie Prot, Céline Pallaud, Semiglazov Vf

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

    AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal... por Sara M. Tolaney, Arlene Chan, Katarína Petráková, Suzette Delaloge, Mario Campone, Hiroji Iwata, Parvin F. Peddi, Peter A. Kaufman, Elisabeth De Kermadec, Qianying Liu, Patrick Cohen, Gautier Paux, Lei Wang, Nils Ternès, Eric Boitier, Seock‐Ah Im

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

    A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer por Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, Pierfranco Conté, Véronique Dièras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders

    Publicado 2020
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer

    Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer por Howard A. Burris, Arlene Chan, Aditya Bardia, J. Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debu Tripathy, Seock‐Ah Im, Stephen Chia, Francisco J. Esteva, Lowell L. Hart, Juan Pablo Zarate, Antonia Ridolfi, Karen Rodriguez Lorenc, Denise A. Yardley

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer por Charles E. Geyer, John Forster, Deborah Lindquist, Stephen Chan, C. Gilles Romieu, Tadeusz Pieńkowski, Agnieszka Jagiełło-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, Mario Campone, Neville Davidson, Mark S. Berger, Cristina Oliva, Stephen D. Rubin, Steven Stein, David Cameron

    Publicado 2006
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial

    Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal,... por W. Eiermann, Tadeusz Pieńkowski, John Crown, Saeed Sadeghi, Miguel Martín, Arlene Chan, Mansoor N. Saleh, Sandeep Sehdev, Louise Provencher, Semiglazov Vf, Michael F. Press, Guido Sauter, Mark A. Lindsay, A. Riva, Marc Buyse, Philippe Drevot, Henry Taupin, John R. Mackey

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    A Phase III Randomized, Double-Blind, Trial Comparing Sorafenib Plus Capecitabine Versus Placebo Plus Capecitabine in the Treatment of Locally Advanced or Metastatic Her2-Negative Breast Cancer (Resilience)

    A Phase III Randomized, Double-Blind, Trial Comparing Sorafenib Plus Capecitabine Versus Placebo Plus Capecitabine in the Treatment of Locally Advanced or Metastatic Her2-Negative... por José Baselga, Claudio Zamagni, P. Gómez, Begoña Bermejo, Shigenori E. Nagai, Bohuslav Melichar, Arlene Chan, L. Mangel, Jonas Bergh, Frederico Costa, Henry Gómez, William J. Gradishar, C. Hudis, Bernardo L. Rapoport, Henri Roché, Patricia Maeda, Liping Huang, Jinghui Zhang, L. Schwartzberg

    Publicado 2014
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

    Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negati... por José Baselga, Patricia Gómez, Richard Greil, Sofía Braga, Miguel Ángel Climent, Andrew Wardley, Bella Kaufman, Salomon M. Stemmer, António Pêgo, Arlene Chan, J. Goeminne, Marie-Pascale Graas, Megan Kennedy, Eva María Ciruelos Gil, Andreas Schneeweiß, Angela Zubel, Jutta Groos, Helena Melezínková, Ahmad Awada

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

    Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized tr... por John R. Mackey, Tadeusz Pieńkowski, John Crown, Saeed Sadeghi, Miguel Martín, Arlene Chan, Mansoor N. Saleh, Sandeep Sehdev, Louise Provencher, Semiglazov Vf, Michael F. Press, Guido Sauter, Mary-Ann Lindsay, Vincent Houé, Marc Buyse, Philippe Drevot, Simon Hitier, Samira Bensfia, W. Eiermann

    Publicado 2016
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

    Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases por J. Randolph Hecht, Steven S. Raman, Arlene Chan, Kevin Kalinsky, Jean‐François Baurain, M.M. Jimenez, Maria Martinez‐García, Martin D. Berger, Ulrich M. Lauer, A. Khattak, Alfredo Carrato, Yue Zhang, K. Liu, Edward Cha, Alissa Keegan, Sumita Bhatta, C.P. Strassburg, Aflah Roohullah

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer

    RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast C... por José Baselga, Claudio Zamagni, Patricia Gómez, Begoña Bermejo, Shigenori E. Nagai, Bohuslav Melichar, Arlene Chan, László Mangel, Jonas Bergh, Frederico Costa, Henry Gómez, William J. Gradishar, Clifford A. Hudis, Bernardo L. Rapoport, Henri Roché, Patricia Maeda, Liping Huang, Gerold Meinhardt, Joshua Zhang, Lee S. Schwartzberg

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial

    Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial por M. Martín Jiménez, F. A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gϋnter von Minckwitz, S. Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Z. Tomasevic, Neelima Denduluri, Robert Šeparović, S-B Kim, EH Jakobsen, R Bryce, Feng Xu, Marc Buyse, Arlene Chan

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: